Clinical Trial Update: Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated two regimens of tamoxifen (Nolvadex) to prevent Casodex-induced gynecomastia in men with prostate cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Casodex (bicalutamide)
• Nolvadex (tamoxifen)

Snippet

Sponsor: AstraZeneca | Conditions: Prostate Cancer | Phase 3 | Status: COMPLETED